Education
About Us
Working with TipRanks
Follow Us
Invivyd (IVVD)
NASDAQ:IVVD
IVVD Stock Chart & Stats
$1.48
-$0.05(-9.00%)
At close: 4:00 PM EST
$1.48
-$0.05(-9.00%)
Day’s Range― - ―
52-Week Range$0.46 - $3.07
Previous CloseN/A
Volume606.77K
Average Volume (3M)3.25M
Market Cap
$451.71M
Enterprise Value$124.77M
Total Cash (Recent Filing)$84.97M
Total Debt (Recent Filing)$2.68M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
Mar 26, 2026EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding277,122,830
10 Day Avg. Volume3,674,869
30 Day Avg. Volume3,251,627
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)0.78
Price to Sales (P/S)2.07
P/FCF Ratio-0.31
Enterprise Value/Market Cap0.28
Enterprise Value/Revenue2.49
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda-2.13
Forecast
1Y Price Target
$10.00Price Target Upside575.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Commercial TractionStronger-than-expected product revenue for PEMGARDA and broad provider uptake, including widespread infusion sites and repeat orders, signal improving commercial momentum that supports launch readiness.
Pipeline DiversificationA newly nominated respiratory syncytial virus antibody demonstrating higher laboratory potency than existing options could expand the company’s addressable market beyond COVID-19 and diversify future revenue streams.
Regulatory ProgressU.S. regulatory alignment on the pivotal program and Fast Track designation for VYD2311 enhances the pathway toward potential approval of an intramuscular antibody alternative to vaccines.
Bears Say
Capital And Dilution RiskAnalyst valuation assumptions include potential equity raises, creating a dilution risk that could reduce per-share returns if additional financing is required.
Clinical And Competitive RiskFailure of VYD2311 or other clinical programs to meet endpoints, or strong competition from alternative prophylactics and vaccines, could significantly weaken valuation and commercial prospects.
Commercial Adoption TimingBroader medical adoption depends on clear trial results and updated treatment guidance, meaning widespread uptake may be delayed and limit near-term revenue growth.
Invivyd News
IVVD FAQ
What was Invivyd’s price range in the past 12 months?
Invivyd lowest stock price was $0.46 and its highest was $3.07 in the past 12 months.
What is Invivyd’s market cap?
Invivyd’s market cap is $451.71M.
When is Invivyd’s upcoming earnings report date?
Invivyd’s upcoming earnings report date is Mar 26, 2026 which is in 41 days.
How were Invivyd’s earnings last quarter?
Invivyd released its earnings results on Nov 06, 2025. The company reported -$0.06 earnings per share for the quarter, beating the consensus estimate of -$0.08 by $0.02.
Is Invivyd overvalued?
According to Wall Street analysts Invivyd’s price is currently Undervalued.
Does Invivyd pay dividends?
Invivyd does not currently pay dividends.
What is Invivyd’s EPS estimate?
Invivyd’s EPS estimate is -0.08.
How many shares outstanding does Invivyd have?
Invivyd has 277,122,830 shares outstanding.
What happened to Invivyd’s price movement after its last earnings report?
Invivyd reported an EPS of -$0.06 in its last earnings report, beating expectations of -$0.08. Following the earnings report the stock price went up 1.316%.
Which hedge fund is a major shareholder of Invivyd?
Currently, no hedge funds are holding shares in IVVD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invivyd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (575.68% Upside)
$10.00 (575.68% Upside)
Blogger Sentiment
Neutral
IVVD Sentiment 67%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 36.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $125.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-27.45%
12-Months-Change
Fundamentals
Return on Equity
-67.94%
Trailing 12-Months
Asset Growth
-14.06%
Trailing 12-Months
Company Description
Invivyd
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
IVVD Company Deck
IVVD Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant positive developments such as FDA feedback for VYD2311, a successful capital raise, and robust revenue growth. However, challenges related to the lack of modern data on COVID vaccines and logistical coordination with FDA centers were noted.View all IVVD earnings summariesIVVD Stock 12 Month Forecast
Average Price Target
$10.00
▲(575.68% Upside)
Technical Analysis
Larimar Therapeutics
―
Rocket Pharmaceuticals
―
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
9.97% Insiders
2.31% Mutual Funds
31.84% Other Institutional Investors
50.52% Public Companies and Individual Investors